Home › Funds › Bellevue Group AG › ABT
Bellevue Group AG position in ABT
ABBOTT LABORATORIES · Health Care
Bellevue Group AG reported holding 947,115 shares of ABT (ABBOTT LABORATORIES) in its Q2 2026 13F filing — a position valued at US$85.9M, representing 1.81% of its reported portfolio and ranking #19 among its reported holdings. Bellevue Group AG has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's ABT position evolved
Bellevue Group AG first disclosed a stake in ABT in Q3 2023 at 1,560,968 shares (US$151.2M). The position peaked in Q2 2025 at 1,564,022 shares, worth US$212.7M. Across 12 filings, Bellevue Group AG increased the stake 3 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 947,115 shares valued at US$85.9M — a reduction of -204,520 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.56M | $151.18M | New |
| Q4 2023 | 1.54M | $169.03M | Reduce |
| Q1 2024 | 1.43M | $163.01M | Reduce |
| Q2 2024 | 1.61M | $166.90M | Add |
| Q3 2024 | 1.74M | $198.83M | Add |
| Q4 2024 | 1.69M | $191.00M | Reduce |
| Q1 2025 | 1.56M | $206.42M | Reduce |
| Q2 2025 | 1.56M | $212.72M | Add |
| Q3 2025 | 1.48M | $198.04M | Reduce |
| Q4 2025 | 1.32M | $165.00M | Reduce |
| Q1 2026 | 1.15M | $118.24M | Reduce |
| Q2 2026 | 947.12K | $85.94M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Sixth Street Partners Management Company, L.P. 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital International Investors 34.65M sh · $3.15B · Q2 2026
- Deutsche Bank AG 16.71M sh · $1.52B · Q2 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held ABT?
Bellevue Group AG has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Bellevue Group AG's current position in ABT?
As of Q2 2026, Bellevue Group AG holds 947.12K shares of ABT (ABBOTT LABORATORIES), valued at $85.94M, representing 1.81% of its reported portfolio and ranking #19.
Has Bellevue Group AG been buying or selling ABT?
In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in ABT. The position peaked in Q2 2025 at 1.56M shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.